



(12) Translation of
European patent specification

(11) NO/EP 2704711 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/40 (2006.01)
A61P 9/12 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.04.19
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.12.02
(86)	European Application Nr.	12779354.5
(86)	European Filing Date	2012.04.30
(87)	The European Application's Publication Date	2014.03.12
(30)	Priority	2011.05.02, US, 201161481317 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	The Board of Trustees of the Leland Stanford Junior University, Office of the General Counsel Building 170, Third Floor, Main Quad P.O. Box 20386, Stanford, CA 94305-2038, USA
(72)	Inventor	SPIEKERKOETTER, Edda, 300 Pasteur Drive Grant S102J, Stanford, CA 94305-5110, USA RABINOVITCH, Marlene, 269 Campus Drive CCSR 1215, Stanford, CA 94305-5162, USA BEACHY, Philip, A., 265 Campus Drive Room G3120A, Stanford, CA 94305-5463, USA SOLOW-CORDERO, David, 269 Campus Drive CCSR Room 0133A, Stanford, CA 94305-5174, USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54)	Title	USE OF FK506 FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
(56)	References Cited:	US-A1- 2005 119 330, WO-A1-2010/031968, US-B2- 6 489 335 YANICK ET AL.: 'Tacrolimus (FK506) and Methotrexate as Prophylaxis for Acute Graft-versus-host Disease in Pediatric Allogenic Stem Cell Transplantation.' BONE MARROW TRANSPLANTATION vol. 26, July 2000, pages 161 - 167, XP055133330 FUJIWARA ET AL.: 'Implications of Mutations of Activin Receptor-like Kinase 1 Gene (ALK1) in addition to Bone Morphogenic Protein Receptor II Gene (BMP2) in Children with Pulmonary Arterial Hypertension.' CIRC J vol. 72, January 2008, pages 127 - 133, XP055133326 MARLENE RABINOVITCH: "Pathobiology of Pulmonary Hypertension", ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, vol. 2, no. 1, 1 February 2007 (2007-02-01), pages 369-399, XP055140979, ISSN: 1553-4006, DOI: 10.1146/annurev.pathol.2.010506.092033

V. ALBINANA ET AL: "Immunosuppressor FK506 Increases Endoglin and Activin Receptor-Like Kinase 1 Expression and Modulates Transforming Growth Factor- 1 Signaling in Endothelial Cells", MOLECULAR PHARMACOLOGY, vol. 79, no. 5, 10 February 2011 (2011-02-10), pages 833-843, XP055140980, ISSN: 0026-895X, DOI: 10.1124/mol.110.067447

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Forbindelse FK506 for anvendelse ved behandling av pulmonal arteriell hypertensjon hos et menneske som har pulmonal arteriell hypertensjon assosiert med defekt BMPR2-signalering, hvor FK506 administreres i en dose som gir en blodkonsentrasjon på under 5 ng/ml.
2. Forbindelse for anvendelse ifølge krav 1, hvor individet har redusert ekspresjon av BMPR2, ALK1 eller endoglin.
3. Forbindelse for anvendelse ifølge krav 1, hvor pasienten har arvelig pulmonal arteriell hypertensjon forårsaket av en mutasjon i BMPR2.
4. Forbindelse for anvendelse ifølge krav 1, hvor pasienten har arvelig pulmonal arteriell hypertensjon forårsaket av en mutasjon i ALK1.
5. Forbindelse for anvendelse ifølge krav 1, hvor pasienten har arvelig pulmonal arteriell hypertensjon forårsaket av en mutasjon i endoglin.
6. Forbindelse for anvendelse ifølge krav 1, hvor doseringen tilveiebringer FK506 blodkonsentrasjon på 0,1 - 0,2 ng/ml.
7. Forbindelse for anvendelse ifølge krav 1, hvor forbindelsen administreres oralt.
8. Forbindelse FK506 for anvendelse i forebygging av pulmonal arteriell hypertensjon assosiert med defekt BMPR2-signalering hos et menneske, hvor FK506 administreres i en dose som gir en blodkonsentrasjon på under 5 ng/ml.